Hepatitis C Clinical Trial
Official title:
Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in Blood
The objectives of the study are to determine the impact of interferon-free treatment for the hepatitis C virus (HCV) on peripheral blood immune cell phenotype and soluble immune-related proteins in blood, while controlling for genetic polymorphisms known to impact HCV-related immune responses, and to determine the impact of the therapy on the emergence of drug-resistant HCV. The study design is informed by the researchers recent investigations of patients receiving HCV treatment. About 4% of patients who had not undergone liver transplantation experienced hepatic decompensating or another serious event. There were several cases of bacterial infection and two cases with elevated markers of autoimmune processes. These events suggest that treatment altered immune responses. About 25% of patients who had undergone liver transplantation experienced hepatic decompensating or another serious adverse event. The long term goal is to understand the pathophysiology of these complications and determine whether HCV treatment can cause an immune reconstitution syndrome in susceptible patients, while improving antimicrobial defenses in others
The objectives of the study are to determine the impact of interferon-free treatment for the
hepatitis C virus (HCV) on peripheral blood immune cell phenotype and soluble immune-related
proteins in blood, while controlling for genetic polymorphisms known to impact HCV-related
immune responses, and to determine the impact of the therapy on the emergence of
drug-resistant HCV. The study design is informed by the researchers' recent investigations of
patients receiving HCV treatment. About 4% of patients who had not undergone liver
transplantation experienced hepatic decompensation or another serious event. There were
several cases of bacterial infection and two cases with elevated markers of autoimmune
processes. These events suggest that treatment altered immune responses. About 25% of
patients who had undergone liver transplantation experienced hepatic decompensation or
another serious adverse event. The long term goal is to understand the pathophysiology of
these complications and determine whether HCV treatment can cause an immune reconstitution
syndrome in susceptible patients, while improving antimicrobial defenses in others The main
questions/objectives to be addressed are (1) to determine the effect of HCV treatment on the
profile of immune cells in blood as assessed by cytometry time of flight (CyTOF)
multiparameter analysis, while controlling for genetic polymorphisms known to be associated
with HCV-related immune responses and, (2) to determine the effect of treatment on
factors/proteins in blood that may be related to immunity and inflammation.
Background: New treatments for HCV are significantly more effective than past treatments.
They utilize direct acting antiviral drugs (DAA) and many do not include interferon. The goal
of treatment is to achieve a sustained virological response (SVR). An SVR is indicated by the
absence of detectable HCV RNA in blood 12 weeks after the end of treatment (EOT); this is
called SVR12. The researchers recently investigated outcomes of 514 non-liver transplant (LT)
patients and 43 LT patients who initiated treatment between Dec 2013 and June 2014. Several
patients developed increased levels of markers of autoimmune processes and/or experienced a
bacterial infection. Investigators at other institutions recently reported evidence that DAA
treatment enhances immune cell activation. The combination of the investigators' observations
and the observations of others indicates that a detailed investigation is needed to
understand the events leading to increased immune cell activity and to determine the factors
that may increase the risk of serious adverse events.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Recruiting |
NCT04510246 -
Link Hepatitis C Notifications to Treatment in Tasmania
|
N/A | |
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03118674 -
Harvoni Treatment Porphyria Cutanea Tarda
|
Phase 2 | |
Completed |
NCT03109457 -
Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
|
||
Completed |
NCT01458054 -
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
|
Phase 1 | |
Completed |
NCT03740230 -
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
|
||
Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Completed |
NCT00006301 -
Immune Response to Hepatitis C Virus
|
||
Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
Recruiting |
NCT04405024 -
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
|
N/A | |
Completed |
NCT04525690 -
Improving Inpatient Screening for Hepatitis C
|
N/A | |
Completed |
NCT04033887 -
Evaluation Study of RDTs Detecting Antibodies Against HCV
|
||
Withdrawn |
NCT04546802 -
HepATocellular Cancer Hcv Therapy Study
|
Phase 3 | |
Active, not recruiting |
NCT02961426 -
Strategic Transformation of the Market of HCV Treatments
|
Phase 2/Phase 3 | |
Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 | |
Completed |
NCT03186313 -
A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection
|
Phase 3 | |
Completed |
NCT02992184 -
PoC-HCV Genedrive Viral Detection Assay Validation Study
|
N/A |